At a glance
- Originator Novartis
- Class Antiasthmatics
- Mechanism of Action Type 3 cyclic nucleotide phosphodiesterase inhibitors; Type 4 cyclic nucleotide phosphodiesterase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Asthma
Most Recent Events
- 23 Jul 1998 No-Development-Reported for Asthma in Japan (Unknown route)
- 26 May 1995 New profile
- 26 May 1995 Preclinical development for Asthma in Japan (Unknown route)